408 related articles for article (PubMed ID: 25109893)
1. Cellular immunotherapy in multiple myeloma: lessons from preclinical models.
Binsfeld M; Fostier K; Muller J; Baron F; Schots R; Beguin Y; Heusschen R; Caers J
Biochim Biophys Acta; 2014 Dec; 1846(2):392-404. PubMed ID: 25109893
[TBL] [Abstract][Full Text] [Related]
2. Immunology and immunotherapeutic approaches in multiple myeloma.
Schlude C; Beckhove P
Recent Results Cancer Res; 2011; 183():97-109. PubMed ID: 21509682
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy using dendritic cells against multiple myeloma: how to improve?
Nguyen-Pham TN; Lee YK; Kim HJ; Lee JJ
Clin Dev Immunol; 2012; 2012():397648. PubMed ID: 22481968
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells in clinical trials for multiple myeloma.
Reichardt VL; Brossart P
Methods Mol Med; 2005; 109():127-36. PubMed ID: 15585918
[TBL] [Abstract][Full Text] [Related]
5. Cellular immunotherapy for multiple myeloma.
Rosenblatt J; Avigan D
Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455
[TBL] [Abstract][Full Text] [Related]
6. Cellular immunotherapy in multiple myeloma.
Vo MC; Lakshmi TJ; Jung SH; Cho D; Park HS; Chu TH; Lee HJ; Kim HJ; Kim SK; Lee JJ
Korean J Intern Med; 2019 Sep; 34(5):954-965. PubMed ID: 30754964
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of multiple myeloma: the start of a long and tortuous journey.
Harrison SJ; Cook G; Nibbs RJ; Prince HM
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1769-85. PubMed ID: 17181491
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for the treatment of multiple myeloma.
Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
[TBL] [Abstract][Full Text] [Related]
9. DC in multiple myeloma immunotherapy.
Turtle CJ; Brown RD; Joshua DE; Hart DN
Cytotherapy; 2004; 6(2):128-37. PubMed ID: 15203989
[TBL] [Abstract][Full Text] [Related]
10. Advances in immunotherapy in multiple myeloma.
Boussi L; Niesvizky R
Curr Opin Oncol; 2017 Nov; 29(6):460-466. PubMed ID: 28877078
[TBL] [Abstract][Full Text] [Related]
11. [Dendritic cell-based immunotherapy for multiple myeloma -- review].
Zhu XJ; He L; Sun XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):821-5. PubMed ID: 19549416
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in multiple myeloma: current strategies and future prospects.
Yi Q
Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
[TBL] [Abstract][Full Text] [Related]
13. Development of Novel Immunotherapies for Multiple Myeloma.
Al-Hujaily EM; Oldham RA; Hari P; Medin JA
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27618026
[TBL] [Abstract][Full Text] [Related]
14. Cellular immunotherapy as a therapeutic approach in multiple myeloma.
Liegel J; Avigan D; Rosenblatt J
Expert Rev Hematol; 2018 Jul; 11(7):525-536. PubMed ID: 29856648
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in multiple myeloma--possibility or probability?
Harrison SJ; Cook G
Br J Haematol; 2005 Aug; 130(3):344-62. PubMed ID: 16042684
[TBL] [Abstract][Full Text] [Related]
16. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
[TBL] [Abstract][Full Text] [Related]
17. Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions.
Verheye E; Bravo Melgar J; Deschoemaeker S; Raes G; Maes A; De Bruyne E; Menu E; Vanderkerken K; Laoui D; De Veirman K
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055096
[TBL] [Abstract][Full Text] [Related]
18. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
[TBL] [Abstract][Full Text] [Related]
19. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.
Rozemuller H; van der Spek E; Bogers-Boer LH; Zwart MC; Verweij V; Emmelot M; Groen RW; Spaapen R; Bloem AC; Lokhorst HM; Mutis T; Martens AC
Haematologica; 2008 Jul; 93(7):1049-57. PubMed ID: 18492693
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for multiple myeloma: Current status and future directions.
Ayed AO; Chang LJ; Moreb JS
Crit Rev Oncol Hematol; 2015 Dec; 96(3):399-412. PubMed ID: 26153389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
